作者
Megan E. Bischoff,Behrouz Shamsaei,Juechen Yang,Dina Secic,Bhargav Vemuri,Julie A. Reisz,Angelo D’Alessandro,Caterina Bartolacci,Rafał Adamczak,L. Ph. H. Schmidt,Jiang Wang,Amelia Martines,Jahnavi Venkat,Vanina T. Tcheuyap,Jacek Biesiada,Catherine A. Behrmann,Katherine E. Vest,James Brugarolas,Pier Paolo Scaglioni,David R. Plas,Krushna C. Patra,Shuchi Gulati,Julio A. Landero Figueroa,Jarek Meller,J. T. Cunningham,Maria Czyzyk-Krzeska
摘要
Abstract Copper (Cu) is a cofactor of cytochrome c oxidase (CuCOX), indispensable for aerobic mitochondrial respiration. This study reveals that advanced clear cell renal cell carcinomas (ccRCCs) accumulate Cu, allocating it to CuCOX. Using a range of orthogonal approaches, including metabolomics, lipidomics, isotope-labeled glucose and glutamine flux analysis, and transcriptomics across tumor samples, cell lines, xenografts, and PDX models, combined with genetic and pharmacological interventions, we explored Cu’s role in ccRCC. Elevated Cu levels stimulate CuCOX biogenesis, providing bioenergetic and biosynthetic benefits that promote tumor growth. This effect is complemented by glucose-dependent glutathione production, which facilitates detoxification and mitigates Cu-H2O2 toxicity. Single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics reveal increased oxidative metabolism, altered glutathione and Cu metabolism, and diminished HIF activity during ccRCC progression. Thus, Cu drives an integrated oncogenic remodeling of bioenergetics, biosynthesis, and redox homeostasis, fueling ccRCC growth, which can be targeted for new therapeutic approaches.